Plastic Surgery Practice is reporting today that a "next generation" neurotoxin based on Botulinum toxin type A is on the way, via an agreement between Medicis Corporation and Revance Therapeutics.
"Under the terms of the agreement, Medicis will pay Revance $10 million at signing, as well as milestone payments totaling approximately $94 million upon successful completion of certain clinical, regulatory, and commercial milestones; and a royalty based on sales and supply price, the total of which is equivalent to a double-digit percentage of net sales."
The terms of the agreement indicate that nothing will begin happening with this until 2010.
Thanks for reading,
Dr. David J. Goldberg
Sanctuary Medical Aesthetic Center, Boca Raton
Skin Laser Surgery Specialists of NY/NJ